Paul Nioi is Senior Vice President of Discovery Research at Alnylam Pharmaceuticals, where he leads teams advancing RNA interference (RNAi) therapeutics from discovery into clinical development.
He has contributed to multiple first-in-class medicines and pipeline programmes across rare diseases, cardiometabolic conditions and neuroscience, using human genetics and genomics to inform target selection and accelerate clinical proof-of-concept.
Previously, Paul held scientific leadership roles at Amgen and Schering-Plough. He also serves on advisory and industry boards, including the Rett Syndrome Research Trust, and has contributed to UK health research initiatives such as Our Future Health.
Paul holds a PhD in Molecular Biology from the University of Dundee and a BSc in Pharmacology from the University of Edinburgh.
